Drug General Information (ID: DDIVLA5HGR)
Drug Name			Cisplatin		Drug Info		Bumetanide		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antineoplastics				Diuretics
Structure

Mechanism of Cisplatin-Bumetanide Interaction (Severity Level: Moderate)
Increased risk of ototoxicity Click to Show/Hide Mechanism Graph
Drug Name		Cisplatin				Bumetanide
Mechanism		Ototoxicity				Ototoxicity
Key Mechanism Factor 1
		Factor Name		Ototoxicity
		Factor Description		Ototoxicity is the damage to the organs of hearing and/or balance following exposure to drugs or chemicals that affect the inner ear. Ototoxic drugs can impair hearing, balance, or both.
Mechanism Description		Increased risk of ototoxicity by the combination of Cisplatin and Bumetanide

Recommended Action
Management		This combination should be avoided unless the potential benefit outweighs the risk. Audiometric testing is recommended if these drugs are given concurrently. Patients should be advised to promptly notify their physician if they experience hearing loss or tinnitus.

References
1	Komune S, Snow JB "Potentiating effects of cisplatin and ethacrynic acid in ototoxicity." Arch Otolaryngol 107 (1981): 594-7. [PMID: 7197152]
2	Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O "Understanding platinum-induced ototoxicity." Trends Pharmacol Sci 34 (2013): 458-69. [PMID: 23769626]
3	Parsons SK, Neault MW, Lehmann, et al "Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma." Bone Marrow Transplant 22 (1998): 669-74. [PMID: 9818694]
4	Product Information. Edecrin (ethacrynic acid). Merck & Co, Inc, West Point, PA.
5	Rhodes T, Twentyman PR "A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug-resistant cell lines." Br J Cancer 65 (1992): 684-90. [PMID: 1316774]
6	Brock PR, Knight KR, Freyer DR, et al. "Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale." J Clin Oncol 30 (2012): 2408-17. [PMID: 22547603]